Publications & Presentations


March 2017 | ARQ 087 / Pre-clinicalARQ 092 / Pre-clinical
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor.
Anticancer Drugs
Presented by: Y. Yu, et al.

February 2017 | ARQ 087 / Pre-clinical
Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models
Translational Oncology
Presented by: R. Chila, et al.

December 2016 | ARQ 531 / Pre-clinical
The Bruton’s Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia
American Society of Hematology (ASH) Annual Meeting 2016
Presented by: S. Reiff, et al.

December 2016 | ARQ 092 / Pre-clinical
Specific inhibition of AKT with ARQ 092, an orally-available selective AKT inhibitor, attenuates acute vaso-occlusive events in sickle cell disease
American Society of Hematology (ASH) Annual Meeting 2016
Presented by: J. Li, et al.

November 2016 | ARQ 092 / Pre-clinical
In vivo Efficacy of the AKT Inhibitor ARQ 092 in Noonan Syndrome With Multiple Lentigines-Associated Hypertrophic Cardiomyopathy
American Heart Associate (AHA)
Presented by: J. Wang, et al.

November 2016 | ARQ 092 / Pre-clinical
Combination treatment by AKT inhibitor ARQ 092 and Sorafenib in a cirrhotic rat model with hepatocellular carcinoma
American Association for the Study of Liver Diseases (AASLD)
Presented by: Z. Jilkova, et al.

October 2016 | ARQ 092 / Pre-clinical
ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease.
Haematologica
Presented by: K. Kim, et al.

October 2016 | Tivantinib / HCC
Prognostic value of the neutrophil-to-lymphocyte ratio in advanced hepatocellular carcinoma: an exploratory analysis from the ARQ 197-215 study
ESMO Congress 2016, Copenhagen, Denmark
Presented by: N. Personeni, et al.

September 2016 | ARQ 092 / Pre-clinical
Dual inhibition of AKT and KIT is synergistic in Gastrointestinal Stromal Tumor
Discovery on Target 2016, Boston, MA
Presented by: P. Zook, et al.

September 2016 | ARQ 087 / Pre-clinical
ARQ 087 inhibits fibroblast growth factor receptor (FGFR) signaling and rescues aberrant cell proliferation and differentiation in experimental models to craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3
EMBO Workshop - The modularity of signalling proteins and networks, Seefield in Tirol, Austria
Presented by: P. Krejci, et al.

September 2016 | ARQ 087 / Pre-clinical
Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation
PLOS ONE
Presented by: T. Hall et al.

September 2016 | ARQ 531 / Pre-clinical
Targeting Ibrutinib-Resistant BTK-C48S1 Mutation with ARQ 531, a Reversible Non-Covalent Inhibitor of BTK
2016 Society of Hematologic Oncology Fourth Annual Meeting, Houston, TX
Presented by: S. Eathiraj, et al.

September 2016 | Tivantinib / HCC
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
Oncotarget
Presented by: L. Rimassa, et al.

July 2016 | ARQ 531 / Pre-clinical
ARQ 531, a Novel, Oral, Non-Covalent Inhibitor of Wild Type and C481S Mutant BTK with Potent Anti-Tumor Activity
2016 Pan Pacific Lymphoma Conference, Koloa, Hawaii
Presented by: S. Eathiraj, et al.

June 2016 | ARQ 087 / iCCA
ARQ 087, an Oral Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitor, in Patients with Advanced and/or Metastatic Intrahepatic Cholangiocarcinoma (iCCA)
ESMO GI 2016, Barcelona, Spain
Presented by: I. Tumori, et al.

June 2016 | ARQ 092 / Pre-clinical
Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor.
Journal of Medicinal Chemistry
Presented by: JM. Lapierre, et al.

May 2016 | ARQ 092 / Pre-clinical
In vitro studies with an AKT inhibitor, ARQ 092, provide evidence for a new and more effective therapeutic option in PIK3CA Related Overgrowth Spectrum (PROS) patients
ESHG 2016, Barcelona, Spain
Presented by: D.C. Loconte, et al.

May 2016 | ARQ 092 / Pre-clinical
Efficacy of AKT inhibitor AR 092 compared with sorafenib in a cirrhotic rat model with hepatocellular carcinoma
EASL 2016, Barcelona, Spain
Presented by: G. Roth, et al.

April 2016 | ARQ 751
In Vitro and in Vivo Anti-tumor Activity of ARQ 751, a Potent and Selective AKT Inhibitor
AACR 2016, New Orleans
Presented by: Y. Yu, et al.

February 2016 | Tivantinib / CRC
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy
International Journal of Cancer
Presented by: C. Eng, e.t al.

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300